Key facts
- Pillar Biosciences’s last known valuation is $309.0M (May 2025).
- It has raised $120.9M across 2 recorded rounds; the latest was Early Stage VC ($20.0M) in May 2021.
- Notable investors include Oriental Fortune Capital, ZhenFund, Infinity Group, Soleus Capital, China Biotech Services Holdings — 8 tracked in total.
- Pillar Biosciences has filed 2 Form Ds with the SEC since 2020, most recently Jun 2021 ($20.0M sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Pillar Biosciences
Funding rounds
2 roundsAbout Pillar Biosciences
Developer of a next-generation sequencing platform designed to support treatment selection through accurate testing across different stages of cancer care. The company offers proprietary technologies, including SLIMamp and PiVAT, enabling clinicians, prescribers, and patients to access localized diagnostics with lower costs, quicker data delivery, and improved testing access.
- Sector
- Healthcare
- HQ
- Natick, MA, United States
- Founded
- 2014
- Employees
- 70
- Website
- pillarbiosci.com/
- Ownership
- Privately Held (backing)
Pillar Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pillar Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pillar Biosciences in its N-PORT filings yet. We sweep new filings monthly.